A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

Study identifier:D7060C00001

ClinicalTrials.gov identifier:NCT04198558

EudraCT identifier:2019-002128-33

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers

Medical condition

Chronic Pain

Phase

Phase 1

Healthy volunteers

Yes

Study drug

MEDI0618, MEDI0618, MEDI0618, MEDI0618, MEDI0618, MEDI0618, MEDI0618, MEDI0618, MEDI0618, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo

Sex

All

Actual enrollment

56

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 29 Nov 2019
Primary Completion Date: 23 Feb 2022
Study Completion Date: 23 Feb 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria